Works matching IS 21938210 AND DT 2025 AND VI 15 AND IP 2
Results: 19
CDKN2A Mutation: A Patient's and Physician's Experience.
- Published in:
- Dermatology & Therapy, 2025, v. 15, n. 2, p. 265, doi. 10.1007/s13555-025-01354-w
- By:
- Publication type:
- Article
Implementation Science to Improve the Diagnosis and Management of Hidradenitis Suppurativa: HELyx Study Design Overview.
- Published in:
- Dermatology & Therapy, 2025, v. 15, n. 2, p. 463, doi. 10.1007/s13555-025-01350-0
- By:
- Publication type:
- Article
Healthcare Resource Utilization and Economic Burden of Prurigo Nodularis in the United States.
- Published in:
- Dermatology & Therapy, 2025, v. 15, n. 2, p. 413, doi. 10.1007/s13555-025-01349-7
- By:
- Publication type:
- Article
Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months.
- Published in:
- Dermatology & Therapy, 2025, v. 15, n. 2, p. 381, doi. 10.1007/s13555-025-01342-0
- By:
- Publication type:
- Article
Effectiveness of Tralokinumab in Different Phenotypes of Atopic Dermatitis: A Real-World Study.
- Published in:
- Dermatology & Therapy, 2025, v. 15, n. 2, p. 337, doi. 10.1007/s13555-025-01341-1
- By:
- Publication type:
- Article
Efficacy, Safety, and Cost-effectiveness of Zinc Oxide Nanoparticles in Whitfield's Spirit Solution for Treating Superficial Fungal Foot Infections: A Randomized Controlled Trial.
- Published in:
- Dermatology & Therapy, 2025, v. 15, n. 2, p. 351, doi. 10.1007/s13555-025-01340-2
- By:
- Publication type:
- Article
Real-Life Experience with Tildrakizumab in Plaque Psoriasis with Palmoplantar Involvement: A Multi-Center Retrospective Italian Study.
- Published in:
- Dermatology & Therapy, 2025, v. 15, n. 2, p. 323, doi. 10.1007/s13555-025-01339-9
- By:
- Publication type:
- Article
Management of Systemic Anti-psoriatic Drugs in Psoriasis Patients with Concurrent Paraplegia or Tetraplegia: Insights From a 6-Year Multicenter, Retrospective Observational Study.
- Published in:
- Dermatology & Therapy, 2025, v. 15, n. 2, p. 427, doi. 10.1007/s13555-025-01338-w
- By:
- Publication type:
- Article
Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials.
- Published in:
- Dermatology & Therapy, 2025, v. 15, n. 2, p. 453, doi. 10.1007/s13555-025-01337-x
- By:
- Publication type:
- Article
Association Between Local Skin Reactions and Efficacy with 5-Fluorouracil 4% Cream in Actinic Keratosis: A Post-Hoc Analysis of Two Randomised Clinical Trials.
- Published in:
- Dermatology & Therapy, 2025, v. 15, n. 2, p. 307, doi. 10.1007/s13555-024-01336-4
- By:
- Publication type:
- Article
Application of Ultraviolet-Induced Fluorescence Trichoscopy (UVFT) in Hair and Scalp Diseases.
- Published in:
- Dermatology & Therapy, 2025, v. 15, n. 2, p. 269, doi. 10.1007/s13555-024-01335-5
- By:
- Publication type:
- Article
Quality of Life in Adults with Atopic Dermatitis in Relation to Disease Severity: Nationwide Data in Japan.
- Published in:
- Dermatology & Therapy, 2025, v. 15, n. 2, p. 291, doi. 10.1007/s13555-024-01333-7
- By:
- Publication type:
- Article
Baricitinib Provides Significant Improvements in Quality of Life and Functioning in Adults with Moderate-to-Severe Atopic Dermatitis with Baseline Body Surface Area ≤ 40% and Severe Itch.
- Published in:
- Dermatology & Therapy, 2025, v. 15, n. 2, p. 437, doi. 10.1007/s13555-024-01330-w
- By:
- Publication type:
- Article
A Real-World Approach to Trifarotene Treatment in Patients with Acne and Acne Sequelae Based on the Experience of the Italian Acne Board.
- Published in:
- Dermatology & Therapy, 2025, v. 15, n. 2, p. 245, doi. 10.1007/s13555-024-01329-3
- By:
- Publication type:
- Article
Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study.
- Published in:
- 2025
- By:
- Publication type:
- Correction Notice
Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological Conditions.
- Published in:
- Dermatology & Therapy, 2025, v. 15, n. 2, p. 395, doi. 10.1007/s13555-024-01325-7
- By:
- Publication type:
- Article
Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE.
- Published in:
- Dermatology & Therapy, 2025, v. 15, n. 2, p. 367, doi. 10.1007/s13555-024-01320-y
- By:
- Publication type:
- Article
Correction: Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis.
- Published in:
- 2025
- By:
- Publication type:
- Correction Notice
A Retrospective Study of Pediatric Allergic Contact Dermatitis from 2017–2022.
- Published in:
- Dermatology & Therapy, 2025, v. 15, n. 2, p. 445, doi. 10.1007/s13555-024-01314-w
- By:
- Publication type:
- Article